Correction: EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines

In this article (Clin Cancer Res 2009;15:575361), which was published in the September 15, 2009 issue of Clinical Cancer Research (1), the disclosure of potential conflicts of interest statement was incorrect. The correct is, as follows:

Dorine Bax, Nathalie Gaspar, Suzanne Little, Lynley Marshall, Lara Perryman, Marta Viani-Pereira, Raisa Vuononvirta, Swee Sharp, Jorge Reis-Filho, Andrew Pearson, Paul Workman, and Chris Jones are or were employees of The Institute of Cancer Research, which has a commercial interest in the development of PI3K inhibitors and operates a rewards-to-inventors scheme. Paul Workman and his team have been involved in a commercial collaboration with Yamanouchi (now Astellas Pharma) and with Piramed Pharma, and intellectual property arising from the program has been licensed to Genentech. Paul Workman was a founder of, consultant to, Scientific Advisory Board member of, and stockholder in Piramed Pharma, which was acquired by Roche, and was formerly an employee of AstraZeneca.